CS
HAE icon

Candriam SCA’s Haemonetics HAE Stock Holding History

Candriam SCA’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,316
Closed -$454K – 702
2024
Q1 		$454K Buy
+5,316
New +$417K ﹤0.01% 659
2023
Q2 		– Sell
-6,123
Closed -$466K – 792
2023
Q1 		$466K Buy
+6,123
New +$496K ﹤0.01% 783
2018
Q3 		– Sell
-5,000
Closed -$448K – 822
2018
Q2 		$448K Buy
+5,000
New +$422K 0.01% 707

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's HAE Position: Q2 2024 in Review

Candriam SCA sold out of Haemonetics (HAE) in Q2 2024, closing a stake of 5,316 shares — an estimated $454K sold.

Candriam SCA first reported a position in HAE in Q2 2018 and held it in 3 quarters. The position peaked at $466K in Q1 2023. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • Candriam SCA reported no remaining Haemonetics position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 5,316 Haemonetics shares in Q2 2024, an estimated $454K.
  • Candriam SCA first reported a position in Haemonetics in Q2 2018 and held it in 3 quarters.
  • Candriam SCA's Haemonetics position peaked at $466K in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.